Medical AI: Anthropic expands globally with OpenEvidence

AI startup Anthropic and medical knowledge platform OpenEvidence announced a partnership on September 22, 2026, that brings AI-powered clinical decision support to approximately 100 developing and emerging market countries. The platform answers clinical questions from physicians based on peer-reviewed medical research and treatment guidelines. The companies did not disclose financial details of the cooperation.

42 million monthly queries demonstrate market potential

Usage figures from the US illustrate the commercial potential of Medical AI: In August 2026, OpenEvidence recorded 42 million queries from US physicians in a single month, as founder Daniel Nadler reported. Nadler predicts that by the end of 2026, several hundred million Americans will have been treated by a physician using OpenEvidence to support treatment. The platform is already available free of charge to clinicians in the US and Europe.

Health systems worldwide are examining whether generative AI can address the shortage of physicians and specialists. Proponents argue that AI tools help medical professionals quickly search through large volumes of medical information. Critics warn, however, that systems trained primarily on data from high-income countries do not reflect local clinical practices – a point the partnership explicitly addresses through regional customization.

Technology division and regional customization

Anthropic provides the backend technology, while OpenEvidence handles regional customization. The companies emphasized that the technology is advanced enough to enable this expansion. However, Anthropic President Daniela Amodei noted that market incentives alone would not have enabled this development without entrepreneurial, philanthropically-oriented work.

OpenEvidence had already begun regional customization efforts prior to the comprehensive partnership announcement. In January 2026, the company launched a collaboration in Rwanda with the Rwanda Biomedical Center and nonprofit Resolve to Save Lives. 45 Rwandan doctors and nurses tested the system and provided feedback on how it could better reflect local clinical conditions. This was complemented by a collaboration with health organizations in Botswana to adapt tools for settings where disease patterns, diagnostic resources, and available treatments differ significantly from wealthier countries.

Target regions with severely limited healthcare access

The initiative targets countries such as Uganda, Angola, Sudan, Haiti, and Mongolia, where access to medical literature, specialists, and continuing medical education is severely restricted. The need is particularly evident in crisis regions with massively disrupted health infrastructure.

In Sudan, according to a WHO statement from April 14, 2026, 37 percent of health facilities in 18 states were non-functional – a result of an armed conflict that had been ongoing since April 2023 and lasted more than three years. 21 million people had no access to health services, and since the conflict began, 217 verified attacks on health facilities had been registered. Disease outbreaks and malnutrition further increased pressure on remaining health systems.

In conflict areas in the Middle East, according to the WHO, an escalation that began on February 28, 2026, resulted in deaths and injuries among civilians and health personnel, damaged medical facilities, disrupted treatment for injuries and chronic diseases, and disrupted air and sea routes, compromising the supply of medical equipment and humanitarian goods.

Equity principle as business model

OpenEvidence founder Daniel Nadler formulated the core principle of the initiative: "Access to medical knowledge should not depend on geography." This equity principle combines philanthropic approach with market expansion – a model also observed in other technology companies that first establish free basic versions in underserved markets.

Anthropic expands biology activities in parallel

Just the week before, on September 18, 2026, Reuters reported that Anthropic had established its own biology lab to conduct hands-on biology work as part of its AI ambitions in drug research. This expansion occurred against a backdrop of public concerns about AI's expanding reach – some executives and lawmakers are calling for a slowdown in AI development.

Anthropic's parallel activities in medical AI infrastructure and biological research suggest a broader strategy to establish a position in the growing health sector. For investors in the DACH region, the Medical AI segment has so far been accessible primarily through publicly listed healthcare companies with AI partnerships or specialized healthcare funds, as most leading AI startups like Anthropic are privately funded.